CNTA
Closed
Centessa Pharmaceuticals Plc Adr
13.17
+0.03 (+0.23%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 13.14
Day's Range: 12.9 - 13.52
Send
sign up or login to leave a comment!
When Written:
3.85
Centessa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company that focuses on developing transformative medicines for patients with rare diseases. The company was founded in 2021 and is headquartered in Cambridge, UK.
Centessa Pharmaceuticals PLC ADR (American Depositary Receipt) is a security that represents ownership in the company's shares, but is traded on a US stock exchange. Each ADR represents a certain number of ordinary shares of the company.
Centessa Pharmaceuticals PLC ADR is listed on the NASDAQ stock exchange under the ticker symbol "CNTA". As of September 2021, the company had a market capitalization of approximately $2.9 billion.
The company's pipeline includes several product candidates in various stages of development for the treatment of rare diseases, including genetic disorders, immunological diseases, and blood disorders. The company's lead product candidate, CNTX-6970, is a potential treatment for patients with autoimmune diseases.
Centessa Pharmaceuticals PLC has a unique business model, which involves operating as a "hub and spoke" organization, with a central management team overseeing several subsidiary companies, each focused on developing a specific product candidate. This model is intended to enable the company to efficiently develop multiple products simultaneously, while also providing flexibility to spin off individual companies if they become more valuable as standalone entities.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Centessa Pharmaceuticals PLC ADR (American Depositary Receipt) is a security that represents ownership in the company's shares, but is traded on a US stock exchange. Each ADR represents a certain number of ordinary shares of the company.
Centessa Pharmaceuticals PLC ADR is listed on the NASDAQ stock exchange under the ticker symbol "CNTA". As of September 2021, the company had a market capitalization of approximately $2.9 billion.
The company's pipeline includes several product candidates in various stages of development for the treatment of rare diseases, including genetic disorders, immunological diseases, and blood disorders. The company's lead product candidate, CNTX-6970, is a potential treatment for patients with autoimmune diseases.
Centessa Pharmaceuticals PLC has a unique business model, which involves operating as a "hub and spoke" organization, with a central management team overseeing several subsidiary companies, each focused on developing a specific product candidate. This model is intended to enable the company to efficiently develop multiple products simultaneously, while also providing flexibility to spin off individual companies if they become more valuable as standalone entities.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!